Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

(2019) M E Robson et al.   ANNALS OF ONCOLOGY

A systematic review of the international prevalence of BRCA mutation in breast cancer

(2019) Nigel Armstrong et al.   Clinical Epidemiology

Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial

(2019) Mark Robson et al.   EUROPEAN JOURNAL OF CANCER

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study

(2018) Ellen R Copson et al.   LANCET ONCOLOGY

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

(2018) Jennifer K. Litton et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician

(2018) Lawrence Blonde et al.   ADVANCES IN THERAPY

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification of novelBRCAfounder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis

(2016) Rong Bu et al.   INTERNATIONAL JOURNAL OF CANCER

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers

(2015) Mohammed Aleskandarany et al.   BREAST CANCER RESEARCH AND TREATMENT

BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study

(2015) Hildegunn Høberg-Vetti et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

The PRECIS-2 tool: designing trials that are fit for purpose

(2015) K. Loudon et al.   BMJ-British Medical Journal

The PRECIS-2 tool: designing trials that are fit for purpose

(2015) K. Loudon et al.   BMJ-British Medical Journal

Prevalence ofBRCA1andBRCA2mutations in unselected breast cancer patients from Peru

(2014) J. Abugattas et al.   CLINICAL GENETICS

Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)

(2012) N. Mavaddat et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer inBRCA1andBRCA2Mutation Carriers

(2009) Mieke Kriege et al.   JOURNAL OF CLINICAL ONCOLOGY